GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (NAS:ADAP) » Definitions » Profitability Rank

Adaptimmune Therapeutics (Adaptimmune Therapeutics) Profitability Rank : 2 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Adaptimmune Therapeutics Profitability Rank?

Adaptimmune Therapeutics has the Profitability Rank of 2. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Adaptimmune Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was -21,582.68%. As of today, Adaptimmune Therapeutics's Piotroski F-Score is 2.


Competitive Comparison of Adaptimmune Therapeutics's Profitability Rank

For the Biotechnology subindustry, Adaptimmune Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adaptimmune Therapeutics's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's Profitability Rank falls into.



Adaptimmune Therapeutics Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Adaptimmune Therapeutics has the Profitability Rank of 2. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Adaptimmune Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-49.856 / 0.231
=-21,582.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Adaptimmune Therapeutics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Good Sign:

Adaptimmune Therapeutics PLC operating margin is expanding. Margin expansion is usually a good sign.

4. Consistency of the profitability

5. Predictability Rank


Adaptimmune Therapeutics Profitability Rank Related Terms

Thank you for viewing the detailed overview of Adaptimmune Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Adaptimmune Therapeutics (Adaptimmune Therapeutics) Business Description

Traded in Other Exchanges
Address
60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, non-small cell lung cancer, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.
Executives
Elliot Norry officer: Chief Medical Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Bertrand William C Jr officer: Chief Operating Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
John Lunger officer: Chief Patient Supply Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Adrian Rawcliffe officer: Chief Financial Officer 440 SOUTH BROAD STREET, UNIT 1906, PHILADELPHIA PA 19146
Kristen Hege director 500 FORBES BLVD, SOUTH SAN FRANCISCO CA 94070
Garry E Menzel director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Priti Hegde director TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Andrew R Allen director 2525 28TH STREET, SUITE 200, BOULDER CO 80301
Cintia Piccina officer: Chief Commercial Officer 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R
Gavin Wood officer: Chief Financial Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Joanna Elizabeth Brewer officer: Chief Scientific Officer 60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Helena Katrina Tayton-martin officer: Chief Operating Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Lawrence M Alleva director 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
James Noble director, officer: Chief Executive Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX

Adaptimmune Therapeutics (Adaptimmune Therapeutics) Headlines

From GuruFocus